Fortive Operating Cash Flow decreased by 35.8% to $234.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 2.9%, from $241.70M to $234.80M. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 3.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $279.50M | $262.20M | $274.60M | $214.80M | $294.40M | $329.80M | $464.20M | $174.40M | $321.00M | $411.40M | $446.80M | $256.70M | $308.90M | $459.00M | $502.20M | $241.70M | $311.20M | $164.40M | $365.90M | $234.80M |
| QoQ Change | — | -6.2% | +4.7% | -21.8% | +37.1% | +12.0% | +40.8% | -62.4% | +84.1% | +28.2% | +8.6% | -42.5% | +20.3% | +48.6% | +9.4% | -51.9% | +28.8% | -47.2% | +122.6% | -35.8% |
| YoY Change | — | — | — | — | +5.3% | +25.8% | +69.0% | -18.8% | +9.0% | +24.7% | -3.7% | +47.2% | -3.8% | +11.6% | +12.4% | -5.8% | +0.7% | -64.2% | -27.1% | -2.9% |